144 related articles for article (PubMed ID: 27171317)
1. Incidence of Occult Uterine Pathology in Women Undergoing Hysterectomy With Pelvic Organ Prolapse Repair.
Ackenbom MF; Giugale LE; Wang Y; Shepherd JP
Female Pelvic Med Reconstr Surg; 2016; 22(5):332-5. PubMed ID: 27171317
[TBL] [Abstract][Full Text] [Related]
2. The incidence of occult malignancy following uterine morcellation: A ten-year single institution experience retrospective cohort study.
Mori KM; Abaid LN; Mendivil AA; Brown JV; Beck TL; Micha JP; Epstein HD; Goldstein BH
Int J Surg; 2018 May; 53():239-242. PubMed ID: 29621658
[TBL] [Abstract][Full Text] [Related]
3. Morcellation and the Incidence of Occult Uterine Malignancy: A Dual-Institution Review.
Picerno TM; Wasson MN; Gonzalez Rios AR; Zuber MJ; Taylor NP; Hoffman MK; Borowsky ME
Int J Gynecol Cancer; 2016 Jan; 26(1):149-55. PubMed ID: 26332395
[TBL] [Abstract][Full Text] [Related]
4. Occult Uterine Malignancy at the Time of Surgery for Pelvic Organ Prolapse: A Systematic Review and Meta-analysis.
Davenport E; James L; Parks T; Howard DL
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e282-e289. PubMed ID: 32604198
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Occult Malignancy Within Morcellated Specimens Removed During Laparoscopic Sacrocolpopexy.
Vallabh-Patel V; Saiz C; Salamon C; Francis A; Pagnillo J; Culligan P
Female Pelvic Med Reconstr Surg; 2016; 22(4):190-3. PubMed ID: 26945272
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation.
Wasson M; Magtibay P; Magtibay P; Magrina J
J Minim Invasive Gynecol; 2017; 24(4):665-669. PubMed ID: 28254678
[TBL] [Abstract][Full Text] [Related]
7. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
8. Are hypertension and diabetes mellitus risk factors for pelvic organ prolapse?
Isık H; Aynıoglu O; Sahbaz A; Selimoglu R; Timur H; Harma M
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():59-62. PubMed ID: 26706923
[TBL] [Abstract][Full Text] [Related]
9. The incidence and risk factors of occult malignancy in patients receiving vaginal hysterectomy for pelvic organ prolapse.
Ryu SM; Cho JS; Kong MK; Bai SW
Int Urogynecol J; 2023 Nov; 34(11):2719-2724. PubMed ID: 37401960
[TBL] [Abstract][Full Text] [Related]
10. Safety of Manual Morcellation After Vaginal or Laparoscopic-assisted Vaginal Hysterectomy.
Balgobin S; Maldonado PA; Chin K; Schaffer JI; Hamid CA
J Minim Invasive Gynecol; 2016; 23(4):542-7. PubMed ID: 26802908
[TBL] [Abstract][Full Text] [Related]
11. Contained specimen morcellation during robotics-assisted laparoscopic supracervical hysterectomy for pelvic organ prolapse.
Falus N; Lazarou G; Gabriel I; Sabatino N; Grigorescu B
Int Urogynecol J; 2023 Nov; 34(11):2783-2789. PubMed ID: 37490062
[TBL] [Abstract][Full Text] [Related]
12. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F; Casarin J; Tortorella L; Huang Y; Weaver A; Angioni S; Melis GB; Mariani A; Stewart EA; Laughlin-Tommaso SK
Am J Obstet Gynecol; 2019 Feb; 220(2):179.e1-179.e10. PubMed ID: 30447212
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
14. Occult Uterine Malignancy at the Time of Sacrocolpopexy in the Context of the Safety Communication on Power Morcellation by the FDA.
Chang OH; Ferrando CA
J Minim Invasive Gynecol; 2021 Apr; 28(4):788-793. PubMed ID: 32681994
[TBL] [Abstract][Full Text] [Related]
15. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
16. Unexpected Significant Uterine Pathological Findings at Vaginal Hysterectomy Despite Unremarkable Preoperative Workup.
Mizrachi Y; Tannus S; Bar J; Sagiv R; Levy T; Condrea A; Ginath S
Isr Med Assoc J; 2017 Oct; 19(10):631-634. PubMed ID: 29103241
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB; Wright JD; Gross CP; Lin H; Boscoe FP; Hutchison LM; Schwartz PE; Xu X
Am J Obstet Gynecol; 2019 Jul; 221(1):39.e1-39.e14. PubMed ID: 30853364
[TBL] [Abstract][Full Text] [Related]
18. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
19. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease.
Von Bargen EC; Grimes CL; Mishra K; Wang R; Haviland MJ; Hacker MR; Carnevale JA; Estes AJ; Elkadry EA
Int J Gynaecol Obstet; 2017 May; 137(2):123-128. PubMed ID: 28170091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
